دورية أكاديمية
Intra-articular clodronate for the treatment of knee osteoarthritis: Dose ranging study vs hyaluronic acid
| العنوان: | Intra-articular clodronate for the treatment of knee osteoarthritis: Dose ranging study vs hyaluronic acid |
|---|---|
| المؤلفون: | Rossini M., Viapiana O., Ramonda R., Bianchi G., Olivieri I., Lapadula G., Adami S. |
| المساهمون: | Rossini, M., Viapiana, O., Ramonda, R., Bianchi, G., Olivieri, I., Lapadula, G., Adami, S. |
| بيانات النشر: | OXFORD UNIV PRESS |
| سنة النشر: | 2009 |
| المجموعة: | Padua Research Archive (IRIS - Università degli Studi di Padova) |
| مصطلحات موضوعية: | Bisphosphonate, Bone, Cartilage, Clodronate, Hyaluronic acid, Intra-articular treatment, Knee, Mobility, Osteoarthriti, Pain, Aged, Analysis of Variance, Bone Density Conservation Agent, Clodronic Acid, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Human, Injections, Intra-Articular, Knee Joint, Male, Middle Aged, Osteoarthritis, Pain Measurement, Range of Motion, Articular, Treatment Outcome |
| الوصف: | OBJECTIVE: Bisphosphonates may have a chondroprotective effect in patients with knee OA (KOA), but the results of clinical trials with oral bisphosphonates have been contradictory. In this Phase 2 randomized, partially blind clinical trial, we tested the efficacy of IA clodronate vs HA in patients with primary KOA. METHODS: One hundred and fifty men or women aged 50-75 years suffering from KOA were randomized to one of five IA therapies: (i) clodronate 0.5 mg one IA injection/week for 4 weeks; (ii) clodronate 1 mg one IA injection/week for 4 weeks; (iii) clodronate 2 mg one IA injection/week for 4 weeks; (iv) clodronate 1 mg two IA injections/week for 2 weeks (clodronate 1 + 1 mg); and (v) HA 20 mg one IA injection/week for 4 weeks. RESULTS: Visual analogue scores (VASs) for different types of pain and the Lequesne index significantly improved in all treatment groups after the first injection and continued to improve even 2-4 weeks after the last injection without significant difference among the groups. A significant (P = 0.03) linear trend for a dose-response (0.5-2 mg clodronate) relationship was found for active movement VAS pain. Both joint extension and mobility scores improved significantly at all time points in all treatment groups without statistical differences among them. CONCLUSIONS: This study indicates that IA clodronate provides symptomatic and functional improvements at least as good as those obtained with HA. Trial Registration. Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali - Agenzia Italiana del Farmaco. Comitato Etico Azienda Ospedaliera Universitaria Senese number CLIO 22/02 http://oss-sper-clin.agenziafarmaco.itTest. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/19406908; info:eu-repo/semantics/altIdentifier/wos/WOS:000267227400012; volume:48; issue:7; firstpage:773; lastpage:778; numberofpages:6; journal:RHEUMATOLOGY; http://hdl.handle.net/11577/3309404Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-67650070025 |
| DOI: | 10.1093/rheumatology/kep084 |
| الإتاحة: | https://doi.org/10.1093/rheumatology/kep084Test http://hdl.handle.net/11577/3309404Test |
| رقم الانضمام: | edsbas.F8EBE85E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/rheumatology/kep084 |
|---|